AI Engines For more Details: Perplexity Kagi Labs You
Blood Sugar Regulation: High amylose cornstarch has been shown to have a low glycemic index, meaning it does not cause rapid spikes in blood sugar levels after consumption. This property makes it beneficial for individuals with diabetes or those at risk of developing diabetes, as it helps maintain more stable blood sugar levels.
Weight Management: Resistant starches like high amylose cornstarch can contribute to weight management by increasing feelings of fullness and reducing overall calorie intake. By promoting satiety and reducing hunger, HACS may help individuals control their appetite and manage their weight more effectively.
Digestive Health: Resistant starches like HACS act as prebiotics, providing fuel for beneficial bacteria in the gut. This fermentation process produces short-chain fatty acids (SCFAs), which help nourish the cells lining the colon and promote a healthy gut microbiota composition. As a result, HACS may support digestive health and reduce the risk of gastrointestinal disorders such as constipation and irritable bowel syndrome (IBS).
Cholesterol Levels: Some studies suggest that consumption of resistant starches like HACS may have a positive impact on cholesterol levels. By reducing the absorption of cholesterol and bile acids in the gut, HACS may help lower LDL cholesterol levels and improve overall lipid profiles, which can lower the risk of cardiovascular disease.
Colon Cancer Risk: The fermentation of resistant starches in the colon produces butyrate, a type of SCFA that has been associated with potential anti-cancer effects. Butyrate helps maintain the health of colon cells and may reduce the risk of colon cancer development.
Improved Insulin Sensitivity: Regular consumption of high amylose cornstarch may improve insulin sensitivity, which is beneficial for individuals with insulin resistance or metabolic syndrome. By enhancing insulin sensitivity, HACS may help regulate blood sugar levels more effectively and reduce the risk of type 2 diabetes.
Bone Health: Some research suggests that resistant starches like HACS may have benefits for bone health by enhancing calcium absorption in the colon. By improving calcium utilization and bone mineral density, HACS may help reduce the risk of osteoporosis and maintain skeletal health.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Increases |
species | Bifidobacterium bifidum | Increases |
species | Bifidobacterium breve | Increases |
species | Bifidobacterium catenulatum | Increases |
species | Bifidobacterium longum | Increases |
species | Bifidobacterium pseudocatenulatum | Increases |
subspecies | Bifidobacterium longum subsp. infantis | Increases |
subspecies | Bifidobacterium longum subsp. longum | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.4 | 0.4 | |
ADHD | 2.5 | -2.5 | |
Allergic Rhinitis (Hay Fever) | 1.5 | 1.5 | |
Allergies | 1.6 | 1.4 | 0.14 |
Allergy to milk products | 1 | 0.3 | 2.33 |
Alopecia (Hair Loss) | 0.6 | -0.6 | |
Alzheimer's disease | 1.9 | 1.7 | 0.12 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 1 | -2.33 |
Ankylosing spondylitis | 0.6 | 1.1 | -0.83 |
Anorexia Nervosa | 0.9 | 0.9 | |
Asthma | 0.6 | 0.4 | 0.5 |
Atherosclerosis | 1.1 | -1.1 | |
Atrial fibrillation | 0.4 | 1.4 | -2.5 |
Autism | 3.4 | 1.1 | 2.09 |
Bipolar Disorder | 0.3 | 0.3 | 0 |
Brain Trauma | 1.3 | -1.3 | |
Carcinoma | 1.4 | 1.4 | 0 |
Celiac Disease | 2.2 | 0.2 | 10 |
Cerebral Palsy | 0.6 | 0.4 | 0.5 |
Chronic Fatigue Syndrome | 0.4 | 0.8 | -1 |
Chronic Kidney Disease | 0.6 | 0.2 | 2 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | |
Coagulation / Micro clot triggering bacteria | 0.6 | 0.6 | |
Colorectal Cancer | 0.8 | 0.8 | 0 |
Constipation | 0.3 | 0.3 | 0 |
Coronary artery disease | 0.3 | 0.6 | -1 |
COVID-19 | 3.3 | 2.5 | 0.32 |
Crohn's Disease | 2.8 | 1.4 | 1 |
cystic fibrosis | 0.4 | 0.4 | |
deep vein thrombosis | 0.3 | 0.3 | |
Depression | 2.8 | 2.9 | -0.04 |
Dermatomyositis | 0.4 | 0.4 | |
Eczema | 1 | 1 | |
Endometriosis | 0.8 | 0.9 | -0.13 |
Epilepsy | 0.8 | 1.1 | -0.38 |
Fibromyalgia | 0.4 | 0.3 | 0.33 |
Functional constipation / chronic idiopathic constipation | 0.4 | 1.5 | -2.75 |
gallstone disease (gsd) | 0.4 | 0.6 | -0.5 |
Generalized anxiety disorder | 0.9 | 0.3 | 2 |
Graves' disease | 0.6 | 0.8 | -0.33 |
Hashimoto's thyroiditis | 0.4 | 0.8 | -1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 1.3 | -0.44 |
hyperglycemia | 0.8 | 0.8 | |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.8 | -1.67 |
hypersomnia | 0.3 | 0.3 | |
hypertension (High Blood Pressure | 1.5 | 1.1 | 0.36 |
Hypothyroidism | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 1 | 1 | |
Inflammatory Bowel Disease | 3 | 0.8 | 2.75 |
Insomnia | 0.3 | 0.3 | 0 |
Intracranial aneurysms | 0.3 | 0.6 | -1 |
Irritable Bowel Syndrome | 0.8 | 0.8 | 0 |
Liver Cirrhosis | 0.8 | 1.1 | -0.38 |
Long COVID | 4.5 | 2.6 | 0.73 |
Low bone mineral density | 0.3 | 0.3 | |
Lung Cancer | 0.6 | 0.6 | |
ME/CFS with IBS | 0.4 | 0.4 | |
ME/CFS without IBS | 0.4 | 0.4 | |
Menopause | 0.2 | 0.8 | -3 |
Metabolic Syndrome | 3.1 | 2.7 | 0.15 |
Mood Disorders | 3.7 | 3.5 | 0.06 |
multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
Multiple Sclerosis | 0.9 | 1.5 | -0.67 |
Multiple system atrophy (MSA) | 1.3 | 1.3 | |
Neuropathy (all types) | 0.3 | -0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 0.6 | 3.33 |
NonCeliac Gluten Sensitivity | 0.4 | 0.4 | |
Obesity | 1.6 | 2 | -0.25 |
obsessive-compulsive disorder | 0.9 | 0.9 | 0 |
Osteoarthritis | 0.5 | 0.5 | |
Osteoporosis | 0.3 | 0.3 | 0 |
Parkinson's Disease | 1.1 | 1.6 | -0.45 |
Polycystic ovary syndrome | 1 | 0.6 | 0.67 |
Postural orthostatic tachycardia syndrome | 0.4 | 0.4 | |
Premenstrual dysphoric disorder | 1.1 | -1.1 | |
primary biliary cholangitis | 0.3 | 0.3 | |
Psoriasis | 1.7 | -1.7 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 2.8 | -2.5 |
Rosacea | 0.8 | -0.8 | |
Schizophrenia | 2 | 2.2 | -0.1 |
scoliosis | 0.9 | 0.9 | |
Sjögren syndrome | 1.1 | 0.5 | 1.2 |
Sleep Apnea | 0.3 | 1.4 | -3.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 0.8 | 0.4 | 1 |
Systemic Lupus Erythematosus | 1.4 | 0.3 | 3.67 |
Tic Disorder | 0.8 | 0.3 | 1.67 |
Type 1 Diabetes | 0.9 | 0.6 | 0.5 |
Type 2 Diabetes | 1.8 | 2.7 | -0.5 |
Ulcerative colitis | 1.3 | 1.6 | -0.23 |
Unhealthy Ageing | 0.4 | 0.4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.